Please wait while the formulary information is being retrieved.
EVKEEZA (evinacumab-dgnb)
- homozygous inherited high blood cholesterol
150 mg/mL intravenous solution
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 4 weeks
Default screening record
- Infuse 15 mg/kg over 60 minute(s) by intravenous route once a month
- Infuse 15 mg/kg over 60 minute(s) by intravenous route every 4 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Pregnancy
Severe
Moderate
- None
EVKEEZA (evinacumab-dgnb)
- homozygous inherited high blood cholesterol
- None
- Dizziness
- Flu-like symptoms
- Nausea
- Pharyngitis
- Rhinorrhea
More Frequent
Severe
Less Severe
- Anaphylaxis
- Hypersensitivity drug reaction
- Acute abdominal pain
- Constipation
- Fever
- General weakness
- Injection site sequelae
- Muscle weakness
- Nasal congestion
- Pain in extremities
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Evinacumab-dgnb
Safety and effectiveness not established in pediatric patients < 12 years old.
- 1 Day – 12 Years
- Safety and effectiveness not established in pediatric patients < 12 years old.
Evinacumab-dgnb
- Severity Level:
D
- Additional Notes: May cross placenta; animal data suggest toxicity
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Evinacumab-dgnb
Insufficient human data available
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Homozygous familial hypercholesterolemia | |
E78.01 | Familial hypercholesterolemia |
0-9 | A-Z |
---|---|
E78.01 | Familial hypercholesterolemia |
Formulary Reference Tool